Insider Selling: Bioventus Inc. (NYSE:BVS) SVP Sells 3,054 Shares of Stock

Bioventus Inc. (NYSE:BVS) SVP Anthony D’adamio sold 3,054 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $4.75, for a total transaction of $14,506.50. Following the sale, the senior vice president now directly owns 58,242 shares in the company, valued at approximately $276,649.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Anthony D’adamio also recently made the following trade(s):

• On Friday, March 15th, Anthony D’adamio sold 3,125 shares of Bioventus stock. The stock was sold at an average price of $5.46, for a total transaction of $17,062.50.

Bioventus Stock Up 1.3 %

BVS stock opened at $4.70 on Thursday. The firm’s fifty day simple moving average is $4.96 and its 200-day simple moving average is $4.48. The company has a market capitalization of $372.08 million, a P/E ratio of -1.87 and a beta of 0.50. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.53 and a quick ratio of 1.01. Bioventus Inc. has a 12 month low of $0.86 and a 12 month high of $6.08.

Bioventus (NYSE:BVS) last released its quarterly earnings data on Tuesday, March 12th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. The business had revenue of $135.42 million for the quarter, compared to the consensus estimate of $124.84 million. Bioventus had a negative net margin of 30.49% and a positive return on equity of 2.25%. As a group, equities research analysts forecast that Bioventus Inc. will post 0.16 earnings per share for the current year.

Institutional Trading of Bioventus

Large investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. boosted its holdings in shares of Bioventus by 1,845.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,140 shares of the company’s stock valued at $30,000 after acquiring an additional 2,030 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in shares of Bioventus by 123.9% in the 1st quarter. Lazard Asset Management LLC now owns 3,132 shares of the company’s stock valued at $44,000 after acquiring an additional 1,733 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Bioventus by 255.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,593 shares of the company’s stock valued at $52,000 after acquiring an additional 5,454 shares during the last quarter. LPL Financial LLC acquired a new position in shares of Bioventus in the 4th quarter valued at $26,000. Finally, Legal & General Group Plc lifted its stake in shares of Bioventus by 267.1% in the 2nd quarter. Legal & General Group Plc now owns 10,121 shares of the company’s stock valued at $69,000 after purchasing an additional 7,364 shares during the period. 62.94% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Craig Hallum boosted their target price on shares of Bioventus from $6.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, March 13th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.